

Press release

Paris & New York, November 29th, 2016

Initiation of coverage by Edison Investment Research

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unsatisfied medical needs in the field of cardiovascular diseases, today announces that Edison Investment Research, an international leading independent investment research company, has just initiated coverage of Quantum Genomics with an initiation note entitled "The next generation of cardiac drugs".

Edison's initiation note is available on the company's website, www.quantum-genomics.com, in the Equity research section of the Investors tab, which already includes Aurgalys and Invest Securities' ones.

Click here to download Edison's initiation note



CONTACTS

Quantum Genomics

Lionel Ségard Chairman & Chief Executive Officer +33 1 85 34 77 77

Quantum Genomics

Marc Karako CFO – Investor Relations +33 1 85 34 77 75

marc.karako@quantum-genomics.com

ACTUS finance & communication (Europe)

Jean-Michel Marmillon **Press Relations** +33 1 53 67 36 73 / immarmillon@actus.fr

The Ruth Group (U.S.)

Lee Roth / Kirsten Thomas Investor / Public Relations +1 646-536-7012 / +1 508-280-6592

ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.

The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).

The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantumgenomics.com.



@ALQGC_EN



in Quantum Genomics